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Objective: This study aimed to evaluate the effects of short-term (60-d) oral supplementation with
calcium fructoborate, resveratrol, and their combination on the clinical and biological statuses of
subjects with stable angina pectoris.
Methods: A randomized, double-blinded, active-controlled, parallel clinical trial was conducted in
three groups of subjects. Of the total number of subjects included in study (n ¼ 166), 87 completed
the 60-d test treatment study period and 29 followed in parallel their usual medical care and
treatment. The primary outcomes were inﬂammation biomarkers (high-sensitivity C-reactive
protein), left ventricular function markers (N-terminal prohormone of brain natriuretic peptide),
and lipid markers (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol, and triacylglycerols). Quality of life was assessed by the Canadian Cardiovascular
Society angina class and the number of angina attacks per week.
Results: There was a signiﬁcant decrease of high-sensitivity C-reactive protein in all groups at the
30-d and 60-d visits. This decrease was greater (39.7% at 60 d) for group 3 (calcium fructoborate),
followed by group 2 (resveratrol plus calcium fructoborate, 30.3% at 60 d). The N-terminal pro-
hormone of brain natriuretic peptide was signiﬁcantly lowered by resveratrol (group 1, 59.7% at
60 d) and by calcium fructoborate (group 3, 52.6% at 60 d). However, their combination (group 2)
was the most effective and induced a decrease of 65.5%. Lipid markers showed slight changes from
baseline in all groups. The improvement in the quality of life was best observed for subjects who
received the resveratrol and calcium fructoborate mixture (group 2).
Conclusion: The results indicate that the combination of resveratrol and calcium fructoborate has
beneﬁcial effects in patients with angina (ClinicalTrials.gov, ISRCTN02337806; March 25, 2010).
 2013 Elsevier Inc. All rights reserved.Introduction
Atherosclerotic ischemicheartdisease is amajorhealthproblem
worldwide [1]. Inﬂammation is a main factor in the initiation,
progression, and acute complications of an atherosclerotic plaque, Ltd. (Romania), project
f Medicine and Pharmacy
fax: þ00-402-5141-5960.
rei).
ll rights reserved.[2]. Resveratrol has shown signiﬁcant cardiovascular protective
effects [3] in models of myocardial injury [4,5], systemic and
pulmonary hypertension [6], and type 2 diabetes [7]. Several car-
dioprotective mechanisms of resveratrol, including antioxidant,
anti-inﬂammatory, and anti-ﬁbrotic actions, have been identiﬁed
[8]. The low in vivo bioavailability caused by rapid resveratrol
metabolism and elimination, its major disadvantages, limits the
results for patient studies [9]. Boron is a bioactive element for
humans and boron-containing compounds present different bio-
logical activities [10]. Calcium fructoborate (CF) is a complex of
calcium, fructose, and boron found naturally in fresh and dried
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the effect of CF on human polymorphonuclear neutrophils and
macrophages, which play a central role in the inﬂammatory
response, has been investigated [13,14]. Two very recent studies
have provided important information on the possible molecular
anti-inﬂammatory activity of CF in the treatment of osteoarthritis
[15,16].
The purpose of this controlled pilot study was to assess the
short-term synergistic effect of resveratrol in combination with
CF on the clinical and biological statuses of subjects with stable
angina pectoris. The combination of these two substances was
based on the fact that CF acts as a stabilizer for resveratrol
degradation in the digestive tract [17]. Furthermore, CF might
present a positive synergism together with resveratrol, in-
creasing the anti-inﬂammatory properties of the former and the
biological efﬁcacy of the latter as an antioxidant agent.
Materials and methods
Study design
The study was randomized, double-blinded, active-controlled, and paralleled
with three groups of subjects who received the test drugs and one control group
of subjects who were not randomized. This single-center trial was approved by
the institutional ethics committee of the Craiova Cardiology Center (Craiova,
Romania) according to decision no. 400 in February 2010. The trial also was in
accord with the Declaration of Helsinki of 1975, which was last reviewed in 2008.
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Fig. 1. Flow chart for subject recruitment. CF, calcium fructoborate; ITT, iconsiderations. Nevertheless, this trial had a control group with subjects who
fulﬁlled inclusion criteria, but they received only their usual medical care and
treatment, without any test materials, during the clinical trial. The number of
total enrolled subjects was 166 (Fig. 1). Of 116 subjects who met the inclusion
criteria, 87 were included in the intention-to-treat analysis, divided into three
groups (29 subjects in each group), and all completed the entire protocol. The
remaining 29 were included in the control group and underwent the same
analysis as those who received the test materials. The subjects’ ages ranged from
42 to 83 years (mean age 65 y). There were more men (71, 61.2%) than women
(45, 38.8%). Most were in Canadian Cardiovascular Society (CCS) angina class III at
inclusion (62%), 30% were in class II, and 8% were in class IV. Table 1 presents the
baseline demographic characteristics of the subjects who successfully completed
the study and the background medication. There were no signiﬁcant differences
among the groups. All subjects continued with their medical therapy as
prescribed by their treating physicians. Subjects did not receive any nutritional
supplements or other products. They were instructed to follow a diet low in salt
or fat if they were hypertensive or dyslipidemic, respectively. Patients with
diabetes mellitus were instructed to follow the recommendation of their treating
physicians.
Inclusion criteria
Male and female subjects at least 18 y of age were included. All had been
diagnosed with angina pectoris (CCS classes II–IV), and they had to be in stable
clinical condition for at least 1 mo (angina class, angina frequency). The subjects’
body mass index range was 24 to 27 kg/m2 (overweight but not obese). Subjects
had to be on standard and stable treatment for angina in the previous month.
Exclusion criteria
Subjects who were unlikely to cooperate in the study, had legal incapacity or
limited legal incapacity, and were pregnant or breast-feeding or had child-Excluded  (n = 50)
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Table 1
Baseline demographic characteristics and concomitant therapy of subjects who
successfully completed the study
Group 1 Group 2 Group 3 Control
Characteristics
Age (y), mean  SD 64.9  5.8 66.3  5.5 63.7  6.2 64.2  7.1
Men/women (n) 17/12 18/11 18/11 18/11
History of MI (%) 41.37 41.37 48.27 44.82
Previous PCI or CABG (%) 13.79 17.24 13.79 13.79
History of hypertension (%) 100 96.55 93.1 96.55
History of DM (%) 44.82 41.37 44.82 41.37
History of PAD (%) 20.68 20.68 17.24 17.24
Medication
b-Blocker (n) 27 26 28 26
ACEI/ARB (n) 23 24 22 23
Calcium channel blocker (n) 8 10 7 5
Nitrate (n) 12 14 11 12
Statin (n) 18 16 21 20
Other lipid-lowering drug (n) 5 7 4 6
Antiplatelets (n) 23 21 25 25
Acenocoumarol (n) 6 7 4 3
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; CABG, coronary artery bypass grafting; DM, diabetes mellitus; MI,
myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous
coronary intervention
Table 2
Changes in hs-CRP and NT-proBNP
Inclusion Month 1 Month 2 P*
hs-CRP (mg/L)
Group 1 6.9  2.5 5.7  1.9 (17.3%) 5.2  1.7 (24.6%) 0.03
Group 2 6.6  2.6 6.2  2.5 (6%) 4.6  1.8 (30.3%) 0.02
Group 3 6.8  1.9 5.3  2.5 (22%) 4.1  1.5 (39.7%) 0.005
Control 6.6  2.4 6.2  2.1 (6%) 5.9  2.6 (10.6%) 0.04
NT-proBNP (pg/mL)
Group 1 674  192 552  232 (18.1%) 271  137 (59.7%) 0.02
Group 2 662  238 498  147 (24.7%) 228  84 (65.5%) 0.01
Group 3 684  151 531  165 (22.3%) 324  102 (52.6%) 0.03
Control 671  218 582  197 (13.2%) 514  207 (23.3%) 0.04
hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal prohormone
of brain natriuretic peptide
Data are presented as mean  SD (percentage of differences from baseline)
* Statistical signiﬁcance from baseline, computed at the end of trial (Student’s
t test).
C. Militaru et al. / Nutrition 29 (2013) 178–183180bearing potential were excluded from the study. Participants in another drug or
device trial at the same time or within the previous 30 d or within ﬁve drug half-
lives of the investigational materials or within the time legally required by the
regulatory authorities, whichever was longer, and those with recent (<3 mo)
hospitalization for unstable angina, myocardial infarction, or coronary revascu-
larizationwere also declared non-eligible for this study. In addition, subjects with
known alcohol or drug abuse, known moderate or severe liver disease (Child–
Pugh score >7), known severe renal disease (serum creatinine >220 mmol/L) or
known anemia (blood hemoglobin <11 g/L), and known chronic inﬂammatory
disease did not participate in the study.
The study used a patented, commercially available dietary supplement that
was previously shown to be identical to a naturally occurring plant-based boron
carbohydrate, i.e., CF [12]. A powdered extract standardized to 50% resveratrol
also was used. Subjects were randomized into three groups for treatment.
Supplementation for the groups was double-blinded. Group 1 received a single
daily capsule of resveratrol 20 mg/d (trans-resveratrol 10.0 mg) in addition to
their usual medical care and treatment. Group 2 received a single daily capsule
of resveratrol 20 mg/d (trans-resveratrol 10.0 mg) combined with CF 112 mg/d
(boron 3.0 mg/d) in addition to their usual medical care and treatment. Group
3 received a single daily capsule of CF 112 mg/d (boron 3.0 mg/d) in addition to
their usual medical care and treatment. The non-randomized control group
received only their usual medical care and treatment.
The daily serving size of CF was based on the recommended daily levels of
boron intake (0.5–7.0 mg/d per person) [18,19]. Using the boron content database
of foods commonly consumed by urban and rural Romanians, the boron intake
was calculated for the population of Craiova and its surroundings and was equal
to 2.0  0.7 mg/d per person (mean  standard deviation) and uniformly
distributed between men and women [15]. During the trial, we did not measure
the CF content from food, but from data in the literature, and knowing the boron
intake for the local population, the CF amount from nutrition should not exceed
5 mg as boron [11].
In humans, less than 5% of the oral dose has been observed as free resveratrol
in blood plasma [9,20]. In our trial, we did not measure plasma levels of
resveratrol because previous research has stated that CF stabilizes resveratrol
degradation in the digestive tract [17]. The optimum amount of resveratrol was
administered to subjects as a function of the amount of boron. The stability ratio
between resveratrol and boron is 1:10. In the present study, we used the
optimum boron concentration for nutrition; thus, the amount of resveratrol
could not have exceeded this determined ratio [17].
The follow-up included three visits: inclusion, at 1 mo (30 d), and at 2 mo
(60 d). The study treatments were well tolerated.
Noninvasive two-dimensional echocardiography was performed only at
inclusion to exclude left ventricular systolic dysfunction or heart failure.
Coronary angiography was not performed because, it is highly unlikely that
a regression of atherosclerotic plaques would be observed in such short time
(e.g., 2 y in one study [21]). Platelet function was not assessed.
Tolerance was evaluated at each visit by asking subjects about the appear-
ance of any adverse events. Compliance was assessed after each subject returned
the test material boxes by counting the remaining capsules and calculating the
percentage of compliance.Statistical analyses
SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used for statistical
analyses. The sample size was determined by a power analysis based on the
preliminary results that were obtained in the cardiology center. After 30 and 60 d,
respectively, differences between mean values obtained for each marker under
evaluation were analyzed using Student’s t test and the Wilcoxon signed-rank
test. The former was used for the primary outcomes (Tables 2 and 3) and the
number of angina episodes and nitroglycerin consumption per week (Table 4),
and the latter was used for Seattle Angina Questionnaire (SAQ) results and CCS
angina class (Table 5). The statistical signiﬁcance was deﬁned at the level of 95%
(P < 0.05) for Student’s t test and the signiﬁcance level was an a value equal to
0.001 for the Wilcoxon signed-rank test. All the obtained results were compared
with baseline values. In Tables 2, 3, and 4, the results are expressed as mean 
standard deviation. In the same tables, values within parentheses represent
the percentage of differences compared with baseline. This was computed as
(x0  x)/x0  100%, where x0 is the initial value (at inclusion) and x the actual
value (after 30 and 60 d, respectively). Owing to the number of subjects (29) in
each group, we chose t repartition, which requires a near-gaussian distribution
of data and similar standard deviations in the compared groups. Before the
statistical analysis, variables were examined for normal distribution as deter-
mined by the Kolmogorov–Smirnov and Shapiro–Wilk tests. To verify the simi-
larity of dispersions, the Levene test was used.
Primary outcome measurements (biochemical parameters)
For biochemical analyses, blood samples of fasting venous blood were taken
in themorning and after 30 d and then 60 d of treatment. Commercial tubes were
used to collect the blood for biochemical parameter determination. Basic
biochemical parameters such as lipid proﬁle (total cholesterol, high-density
lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, and
triacylglycerols) and inﬂammatory markers (serum high-sensitivity C-reactive
protein [hs-CRP]) were analyzed in serum by standard biochemical procedures
using the Cobas Integra 400 Plus automatic analyzer and kits (Roche,
Switzerland). N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
was determined using the Cobas h232 analyzer and tests (Roche Diagnostics
GmbH, Mannheim, Germany).
Secondary outcomes measurements (quality of life)
Secondary outcomes were the CCS angina class as assessed by a physician
during the subject’s interview, the mean number of angina attacks per week,
and the SAQ scores obtained at inclusion and the ﬁnal visit after 60 d. The
questionnaires were completed by the subjects or with the help of a relative or
nurse. Regarding the number of angina episodes per week and nitroglycerin
consumption, subjects were instructed to keep a diary with the number of angina
episodes they had and the number of nitroglycerin tablets they used. The SAQ is
a 19-item questionnaire intended to measure functional status in subjects with
coronary artery disease [22,23].
Safety assessment
Two emergency telephone numbers were given to the subjects to maintain
contact during the study in case of adverse events or other concerns related to
the study. Participants were instructed to inform the test supervisor if they chose
to discontinue the study owing to adverse effects.
Table 3
Changes in lipid proﬁle
Inclusion Month 1 Month 2 P*
Total cholesterol (mg/dL)
Group 1 176.5  89 171.1  97 164.3  79 (6.9%) 0.02
Group 2 167.5  95 165.2  89 163.7  71 (2.2%) 0.04
Group 3 172.5  75 166.8  77 162.2  69 (5.9%) 0.03
Control 169.4  85 166.3  91 164.8  82 (2.7%) 0.04
LDL cholesterol (mg/dL)
Group 1 123.2  63 118.4  59 115.3  57 (6.4%) 0.03
Group 2 118.5  57 115.2  54 113.2  56 (4.4%) 0.04
Group 3 122.6  46 115.1  49 111.2  55 (9.2%) 0.02
Control 121.2  61 118.7  57 116.6  52 (3.7) 0.04
HDL cholesterol (mg/dL)
Group 1 53.2  25 52.8  27 54.1  33 (1.6%) 0.03
Group 2 52.3  45 51.9  27 52.8  35 (0.9%) 0.04
Group 3 50.1  20 51.3  23 52.7  26 (5.1%) 0.03
Control 51.8  23 51.2  32 51.6  29 (0.3%) 0.04
Triacylglycerols (mg/dL)
Group 1 134.1  64 131.2  72 128.8  58 (3.9%) 0.03
Group 2 127.1  72 127.8  67 125.7  68 (1.1%) 0.04
Group 3 137.6  54 135.8  62 132.7  64 (3.5%) 0.03
Control 132.4  69 130.4  81 129.8  72 (1.9%) 0.04
HDL, high-density lipoprotein; LDL, low-density lipoprotein
Data are presented as mean  SD (percentage of differences from baseline)
* Statistical signiﬁcance from baseline, computed at the end of trial (Student’s
t test).
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There was a signiﬁcant decrease of hs-CRP in all groups at the
30-d and 60-d visits (Table 2). This decrease was greater for
group 3 (CF), followed by group 2 (resveratrol plus CF). After 30 d,
group 3 continued to show the greatest decrease (22%), followed
by groups 1 and 2 (almost insigniﬁcant). After 60 d, group 2
exceeded group 1 (30.3% versus 24.6%), but group 3 (CF) still
showed the most signiﬁcant decrease (39.7%).
Table 2 presents the changes in NT-proBNP in all groups. NT-
proBNP was signiﬁcantly lowered by resveratrol (group 1, by
59.7% at 60 d) and by CF (group 3, by 52.6% at 60 d). Their
combination was the most effective (group 2) and induced
a decrease of 65.5% (P ¼ 0.01, statistical signiﬁcance from base-
line). The downward trend for group 2 was the greatest after the
ﬁrst month and at the end of the study. The decrease in the
control group was very low (10.6% for hs-CRP and 23.3% for NT-
proBNP) compared with the other groups.
The lipid proﬁle (Table 3) showed a favorable trend in all
groups. Total cholesterol, LDL cholesterol, and triacylglycerols
decreased, whereas HDL cholesterol increased. Based on the
percentage of differences from baseline computed at the end of
study, the greatest decrease in LDL cholesterol (9.2%) and theTable 4
Angina episodes and weekly nitroglycerin consumption
Inclusion Month 1 Month 2 P*
Angina episodes/wk
Group 1 4.2 3.3 2.1 (50%) 0.02
Group 2 4.4 3.2 1.8 (59%) 0.002
Group 3 4.5 3.5 2.3 (48.8%) 0.02
Control 4.2 3.8 3.2 (23.8%) 0.03
Nitroglycerin consumption
(tablets or puffs/wk)
Group 1 3.2 2.3 1.4 (56.2%) 0.006
Group 2 3.4 2.1 1.1 (67.6%) 0.003
Group 3 3.1 2.4 1.4 (54.8%) 0.007
Control 3.4 2.8 2.4 (29.4%) 0.02
Data are presented as number (percentage of differences from baseline)
* Statistical signiﬁcance from baseline, computed at the end of trial (Student’s
t test).greatest increase in HDL cholesterol (5.1%) were for subjects
taking CF (group 3). Group 1 (resveratrol) presented the most
signiﬁcant decreases for total cholesterol (6.9%) and for tri-
acylglycerols (3.9%), although the latter value was very close to
that obtained for group 3 (3.5%). It is important to note that
during the study, subjects previously prescribed statins by their
treating physician continued their statin therapy. Statins may
have had an inﬂuence on the obtained results, but the results
from the control group were rather low (3.7% versus 9.2% for
LDL cholesterol, 0.3% versus 5.1% for HDL cholesterol, 2.7%
versus 6.9% for total cholesterol, and 1.9% versus 3.9% for
triacylglycerols) compared with groups 1 and 3.
There was an improvement in the subjects’ quality of life in
all groups. Tables 4 and 5 present the signiﬁcant decreases
in the number of angina episodes per week and nitroglycerin
consumption, increases in SAQ scores, and improvement in
angina class in all groups. In Table 4, the improvement in the
quality of life was best observed for subjects in group 2 (resver-
atrol plus CF), because the percentages of differences obtained
from baseline were the highest compared with the other groups.
Thus, the decrease in angina episodes per week was 59%. Nitro-
glycerin consumption followed a similar trend, with a decrease of
67.6%. For groups 1 and 3, the results were comparable and
signiﬁcant: the decreases in angina episodes per week were 50%
for group 1 (resveratrol) and 48.8% for group 3 (CF). For nitro-
glycerin consumption, the decreases after 60 d were 56.2% for
group 1 and 54.8% for group 3. For the control group, the decrease
was almost half (23.8% and 29.4%, respectively) compared with
the other groups.
All SAQ measurements showed a signiﬁcant improvement
from baseline to the 60-d follow-up (Table 5). The greatest
difference was observed in SAQ angina stability, for which the
resveratrol plus CF treatment produced an increase from 44.2
to 86.5. As presented in Table 5, an improvement in CCS angina
class at the 2-mo follow-up in all treatment groupswas observed.
There were signiﬁcantly fewer subjects in classes III and IV;
most were in class II, and only a few subjects were in class I.
Discussion
All subjects in this study had been diagnosed with stable
angina pectoris. Coronary artery disease, the main cause of
angina, is caused by atherosclerosis of the coronary arteries.
Atherosclerosis is an inﬂammatory disease and not merely the
passive accumulation of lipids within the artery walls. The liter-
ature provides information that oxidized LDL is one risk factor
for atherosclerotic inﬂammation. HDL has a protective effect
against the development of atherosclerosis, which results partly
from its anti-inﬂammatory and antioxidant properties [24–26].
Studies of themechanisms of atherosclerosis have suggested that
anti-inﬂammatory and antioxidant agents might be protective
[24,27].
The two substances being tested in this trial, CF and resver-
atrol, werewell tolerated. From the literature, the highest dose of
CF administered was 37.5 mg/kg. No toxicity was noted at this
dosage [28]. Resveratrol presents a low toxicity [29].
Orally ingested boron has been observed to be well absorbed
(>90%) from the gastrointestinal tract in humans, rats, and
rabbits. Boron as borate is readily and almost completely absor-
bed (>90%) from the human gut [30,31]. About 70% of the
resveratrol dose given orally as a pill is absorbed; nevertheless,
the oral bioavailabilityof resveratrol is low because it is rapidly
metabolized in the intestines and liver into conjugated forms,
i.e., glucuronateand sulfonate. Only trace amounts (<5 ng/mL) of
Table 5
SAQ results and CCS angina class*
Group 1 Group 2 Group 3 Control
Baseline Month 2 Baseline Month 2 Baseline Month 2 Baseline Month 2
SAQ
Physical limitations 52.2 64.3 50.5 66.4 53.4 64.4 55.3 59.1
Angina stability 46.7 81.2 44.2 86.5 47.3 82.6 49.3 61.2
Angina frequency 48.6 69.4 46.5 73.1 46.8 70.2 47.2 59.4
Treatment satisfaction 67.5 78.1 68.4 81.3 66.2 78.3 69.1 73.2
Disease perception 33.4 52.1 32.1 54.4 34.7 55.6 34.1 41.2
Visual scale score 63.2 74.5 64.5 77.1 61.8 75.6 62.4 68.1
CCS angina class
I 0 4 0 5 0 7 0 2
II 8 13 8 11 10 13 9 10
III 19 10 18 12 17 8 18 16
IV 2 1 3 1 2 1 2 1
CCS, Canadian Cardiovascular Society; SAQ, Seattle Angina Questionnaire
* P < 0.001 (Wilcoxon signed-rank test).
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a 25-mg oral dose [9].
Boron supplements have been reported to lower the platelet
count and potentially decrease the risk of thrombosis [32], and
experimental evidence has been obtained for the likely useful-
ness of boron-containing thrombin inhibitors in the treatment of
cardiovascular disorders [33]. Recent studies in animal models
have suggested that boron deprivation increases the concentra-
tions of plasma homocysteine [34] and insulin [35], which have
been suggested as risk factors for heart disease.
For this trial, we chose this combination of CF and resveratrol
because previous research has suggested that CF stabilizes
resveratrol degradation in the digestive tract [17], CF has been
shown to be an important anti-inﬂammatory agent [11,15], and
resveratrol has been found to have antioxidant properties [36].
CF also is an antioxidant [11]. The objective was to assess their
synergetic effect on the markers under investigation: inﬂam-
mation, left ventricular function, and lipids.
The increase in CRP levels in the blood is recognized as
a marker of cardiac disease risk, and it has a prognostic value in
coronary artery disease [37]. Regarding the systemic inﬂamma-
tion measured by hs-CRP, the obtained results showed that
resveratrol and especially CF (after 60 d, the decrease was 39.7%)
have the beneﬁcial effects of signiﬁcantly decreasing the hs-CRP
level. The CF results are consistent with previous studies in
which CF in similar serving sizes caused signiﬁcant decreases in
hs-CRP [15,16]. This is further conﬁrmation of the strong
anti-inﬂammatory effects of CF.
The76-amino acidNT-proBNP fragment is themost frequently
used plasmamarker of congestive heart failure [38]. According to
the obtained results, the observed decrease was rather high
(65.5% in group 2).
According to data from the literature, hs-CRP and NT-proBNP
were monitored. Levels of NT-proBNP have been reported to be
signiﬁcantly higher (182.8 pg/mL) in ischemic patients compared
with thosewithout ischemia (88.4 pg/mL), with amedian hs-CRP
level of 2.2 mg/mL [39]. Moreover, in a study of different anti-
anginal therapies, after 12 mo of treatment with valsartan and
enalapril, patients with stable, symptomatic heart failure pre-
sented signiﬁcantly decreased levels of NT-proBNP (15.3%
versus13.6% changes, respectively) andhs-CRP (105.7% versus
73.3% changes, respectively) comparedwithbaseline [40]. In the
present study, hs-CRP and pro-BNP showed signiﬁcant changes
in a relatively short time (2mo). Thisﬁndingopensnewdirections
of research regarding the use of natural adjuvants (CF plus
resveratrol) for improving the standard antianginal therapies.Regarding lipid markers, improvements in levels of LDL
cholesterol and HDL cholesterol were most numerically signiﬁ-
cant in the CF group (group 3), whereas the resveratrol group
(group 1) showed the best results for total cholesterol and tri-
acylglycerols, although the values were rather close to those in
group 3. The observed changes seem small (<10%) but are none-
theless important because any statistically signiﬁcant changes in
these important cardiovascular markers may decrease the risk of
heart disease.
Furthermore, this study showed that the combination of
resveratrol and CF (group 2) elicited signiﬁcant improvements in
the number of angina episodes and nitroglycerin consumption
per week and in the quality of life for subjects with stable angina
pectoris.
In the three experimental groups, CF, resveratrol, and their
combination presented positive effects, with the marker values
being signiﬁcantly different from baseline. For the control group,
some changes were noticed, but these were of little signiﬁcance.
Thus, the addition of this control group to the trial highlights the
improvements in the parameters under investigation in the
presence of CF, resveratrol, or their combination in the other
groups.
Although the study would have been improved by a larger
number of subjects and a longer duration, to our knowledge this
is the ﬁrst clinical study that has evaluated the synergistic effects
of resveratrol and CF in patients with ischemic cardiac disease
from a clinical point of view (symptoms) and the beneﬁcial
effects (anti-inﬂammatory and antioxidant) of their combination
on lipid proﬁles and inﬂammation markers. The obtained data
are promising and represent an important base for further trials
(the next trial has been registered in the international database
at http://www.controlled-trials.com/ISRCTN90543844).
Conclusion
The combination of resveratrol and CF has beneﬁcial effects in
subjects with stable angina pectoris and the outcome of this
study supports the use of these products as dietary supplements
for improving quality of life. This trial is a starting point for
studying the action of a resveratrol and CF mixture in patients
with stable angina.
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